The present invention provides a pharmaceutical composition for use in the treatment of erythema or telangiectasia associated with rosacea by topical administration of the composition, wherein the composition is a cream comprising oxymetazoline or a pharmaceutically acceptable salt thereof and 1% to 50% by weight of an emollient, said emollient comprising medium chain triglycerides diisopropyl adipate, oleyl alcohol, and lanolin. Also provided is a pharmaceutical composition for use in the treatment of erythema or telangiectasia associated with rosacea by topical administration of the composition, wherein the composition is a cream comprising oxymetazoline or a pharmaceutically acceptable salt thereof, and wherein the therapeutic effect of the composition is maintained for at least 27 days after final administration.
